Patents by Inventor David Shewmake

David Shewmake has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090188796
    Abstract: The invention provides a data base of LDL, I, IIa, IIb, IIIa, IIb, IVa, IVb and HDL2a, HDL2b, HDL 3a, HDL 3b and HDL 3c together with patient data such as HDL-C, LDL-C, Apo A, ApoB, Lp(a) and patient personal data useful for treatment, diagnosing, and monitoring cardiovascular disease. The data base contains the LDL and HDL subfraction data in quantitative mg/dl values and permits deriving relationship amongst the LDL and HDL values and cardiovascular disease. Quantitative data permits more effective treatment and monitoring of cardiovascular disease. For example, quantitative differences in LDL and HDL subclass levels can determine the need for more or less aggressive treatment. The data base which includes patient events, procedures, interventions which is correlated to LDL and HDl quantitative subclass data permits development of personalized patient treatment plans and monitoring the effectiveness of such treatment.
    Type: Application
    Filed: August 25, 2008
    Publication date: July 30, 2009
    Applicant: Berkeley HeartLab, Inc.
    Inventors: David Shewmake, Frank Ruderman, Christopher Boggess, Faith Clendenen
  • Patent number: 7416895
    Abstract: This invention is directed to a data base which contains data for HDL2b, LDL IIIa & LDL IIIb and LDL IVb subclasses all in mg/Dl and which is correlated to cardiovascular disease.
    Type: Grant
    Filed: April 12, 2003
    Date of Patent: August 26, 2008
    Assignee: Berkeley Heartlab, Inc.
    Inventors: David Shewmake, Frank Ruderman, Christopher Boggess, Faith Clendenen
  • Publication number: 20070068539
    Abstract: The invention provides a system that determines if a patient has Metabolic Syndrome, and in response provides a disease-management program that helps reduce medical risks associated with this malady. The system features a device configured to collect glucose information and blood pressure information, and then transmit this information to a central computer system. The system also includes a database configured to receive triglyceride information and cholesterol information from an external blood test, and a central computer system featuring: 1) a communication interface configured to communicate with the device to receive glucose and blood pressure information and with the database to receive triglyceride and cholesterol information; 2) a user interface configured to accept patient information; and 3) a processor configured to operate an algorithm that processes the glucose, blood pressure, triglyceride, cholesterol, and patient information to determine if the patient has Metabolic Syndrome.
    Type: Application
    Filed: September 18, 2006
    Publication date: March 29, 2007
    Inventors: Christopher Hall, Vance Lanier, David Shewmake, Frank Ruderman, Matthew Banet, Randon Schultz, Marshal Dhillon, Adam Fleming, Henk Visser
  • Publication number: 20070071643
    Abstract: The invention provides a system for monitoring a patient that includes: 1) a first database that stores the patient's blood test information; 2) a monitoring device that collects the patient's cardiovascular and exercise information; 3) a second database that receives cardiovascular and exercise information from the monitoring device; and 4) an Internet-based system that displays the blood test, cardiovascular, and exercise information.
    Type: Application
    Filed: September 18, 2006
    Publication date: March 29, 2007
    Inventors: Christopher Hall, Vance Lanier, David Shewmake, Frank Ruderman, Matthew Banet, Randon Schultz, Marshal Dhillon, Adam Fleming, Henk Visser
  • Publication number: 20050042761
    Abstract: The invention provides a method for identifying patients with normal NCEP lipid levels who are in need of treatment for cardiovascular disease comprising measuring one or more LDL or HDL particle subclass levels and identifying abnormal LDL or HDL subclass levels. LDL III a+b and HDL 2b are preferred subclasses.
    Type: Application
    Filed: October 6, 2004
    Publication date: February 24, 2005
    Applicant: Berkeley HeartLab, Inc.
    Inventors: David Shewmake, Frank Ruderman, Christopher Boggess
  • Publication number: 20050009193
    Abstract: The invention provides novel methods for selecting an optimal diet and exercise regimen for a patient based on the consideration of several factors, including low density lipoprotein (LDL) and high density lipoprotein (HDL) subclass levels. Furthermore, the invention provides novel methods for treating a patient, comprising selecting an optimal diet and exercise regimen and monitoring the patient. Patients appropriate for the methods of the invention include, for example, those with cardiovascular disease (CVD) or at risk of developing CVD. In contrast to prior methods, the methods of the invention are based on the measurement of risk factors, including LDL and HDL subclass levels, that have not previously been used to select a diet and exercise regimen.
    Type: Application
    Filed: May 26, 2004
    Publication date: January 13, 2005
    Applicant: Berkeley Heartlab, Inc.
    Inventors: Amy Roberts, David Shewmake
  • Patent number: 6812033
    Abstract: The invention provides a method for identifying patients with normal NCEP lipid levels who are in need of treatment for cardiovascular disease comprising measuring one or more LDL or HDL particle subclass levels and identifying abnormal LDL or HDL subclass levels.
    Type: Grant
    Filed: April 12, 2002
    Date of Patent: November 2, 2004
    Assignee: Berkeley HeartLab, Inc.
    Inventors: David Shewmake, Frank Ruderman, Christopher Boggess
  • Publication number: 20030235918
    Abstract: The invention provides a data base of LDL, I, Ia, IIb, IIIa, IIb, IVa, IVb and HDL2a, HDL2b, HDL 3a, HDL 3b and HDL 3c together with patient data such as HDL-C, LDL-C, Apo A, ApoB, Lp(a) and patient personal data useful for treatment, diagnosing, and monitoring cardiovascular disease. The data base contains the LDL and HDL subfraction data in quantitative mg/dl values and permits deriving relationship amongst the LDL and HDL values and cardiovascular disease. Quantitative data permits more effective treatment and monitoring of cardiovascular disease. For example, quantitative differences in LDL and HDL subclass levels can determine the need for more or less aggressive treatment. The data base which includes patient events, procedures, interventions which is correlated to LDL and HD1 quantitative subclass data permits development of personalized patient treatment plans and monitoring the effectiveness of such treatment.
    Type: Application
    Filed: April 12, 2003
    Publication date: December 25, 2003
    Applicant: Berkeley HeartLab, Inc.
    Inventors: David Shewmake, Frank Ruderman, Christopher Boggess, Faith Clendenen
  • Publication number: 20030194812
    Abstract: The invention provides a method for identifying patients with normal NCEP lipid levels who are in need of treatment for cardiovascular disease comprising measuring one or more LDL or HDL particle subclass levels and identifying abnormal LDL or HDL subclass levels.
    Type: Application
    Filed: April 12, 2002
    Publication date: October 16, 2003
    Applicant: Berkeley HeartLab, Inc.
    Inventors: David Shewmake, Frank Ruderman, Christopher Boggess